Physician profile
Christopher P Dehan
NPI 1487740809
$1,636.94
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $256 · 2021: $441 · 2022: $129 · 2023: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $140.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $654.03 | 2019-2021 | |
| Olympus America INC. | $238.86 | 2019-2023 | Rhino-Laryngo Videoscope |
| Aerin Medical INC. | $130.74 | 2019-2021 | |
| Genzyme Corporation | $117.02 | 2021 | |
| Medtronic, INC. | $110.85 | 2022 | |
| Intersect Ent, INC. | $94.82 | 2020-2021 | |
| Acclarent, INC | $74.88 | 2019-2020 | |
| Kaleo, INC. | $66.05 | 2019-2021 | |
| Optinose US, INC. | $38.76 | 2020-2021 | |
| Alk-Abello, INC | $32.27 | 2020-2021 | |
| Itamar Medical INC | $18.36 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $18.03 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.87 | 2019 | |
| Smith+Nephew, INC. | $14.20 | 2021 | |
| Glaxosmithkline, LLC. | $13.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Dehan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.